Compare XBIT & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | CBAT |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | China |
| Employees | 85 | N/A |
| Industry | Pharmaceuticals and Biotechnology | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.0M | 73.3M |
| IPO Year | 2015 | 2006 |
| Metric | XBIT | CBAT |
|---|---|---|
| Price | $2.43 | $0.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.9K | ★ 79.4K |
| Earning Date | 05-13-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $195,189,306.00 |
| Revenue This Year | N/A | $79.15 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $2.09 | $0.69 |
| 52 Week High | $3.61 | $1.25 |
| Indicator | XBIT | CBAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 37.23 |
| Support Level | $2.15 | $0.79 |
| Resistance Level | $2.46 | $0.93 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 70.83 | 37.82 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.